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Abstract
Background: There are currently three ongoing studies on less radical surgery in cervical cancer: ConCerv,
GOG-278, and SHAPE. The aim of this study was to evaluate the performance of the criteria used in ongoing studies
retrospectively and suggest a new, simplified criterion in microscopic Stage IB1 cervical cancer.
Methods: A retrospective analysis was performed in 125 Stage IB1 cervical cancer patients who had no clinically
visible lesions and were allotted based on microscopic findings after conization. All patients had magnetic
resonance imaging (MRI) after conization and underwent type C2 radical hysterectomy. We suggested an MRI
criterion for less radical surgery candidates as patients who had no demonstrable lesions on MRI. The rates of
parametrial involvement (PMI) were estimated for patients that satisfied the inclusion criteria for ongoing studies
and the MRI criterion.
Results: The rate of pathologic PMI was 5.6% (7/125) in the study population. ConCerv and GOG-278 identified 11
(8.8%) and 14 (11.2%) patients, respectively, as less radical surgery candidates, and there were no false negative
cases. SHAPE and MRI criteria identified 78 (62.4%) and 74 (59.2%) patients, respectively, as less radical surgery
candidates; 67 patients were identified as less radical surgery candidates by both sets of criteria. Of these 67
patients, only one had pathologic PMI with tumor emboli.
Conclusions: This study suggests that the criteria used in three ongoing studies and a new, simplified criterion
using MRI can identify candidates for less radical surgery with acceptable false negativity in microscopic Stage IB1
disease.
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Background
Despite the trend for decreasing cervical cancer mortality in
Asian countries, the disease continues to be a major public
health problem [1]. Stage IB1 disease is where the cancer
can be seen without a microscope and is 4 cm or smaller
(macroscopic IB1) or can be seen only with a microscope
and has depth of invasion of more than 5 mm and width of
more than 7 mm (microscopic IB1). We suggested criteria
for less radical surgery in macroscopic IB1 based on pre-
operative magnetic resonance imaging (MRI) parameters in
a previous study [2]. As the risk of parametrial involvement
(PMI) is lower in patients with smaller tumors [3-7], patients
with microscopic Stage IB1 disease are promising candidates
for less radical surgery [2,8]. However, the decision to per-
form parametrectomy and the extent of resection vary
widely in practice [9]. Moreover, although many gynecologic
oncologists agree that women with “low-risk” cervical can-
cer do not require parametrectomy, there is no consensus
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on what constitutes a “low-risk” patient for less radical
surgery.
Currently, two prospective cohort studies and one ran-
domized controlled trial are evaluating less radical surgery
(conization or simple hysterectomy) in patients with low-
risk early-stage cervical cancer [10]. First, the MD Anderson
Cancer Center is conducting a prospective, international,
multi-institutional cohort study (ConCerv) evaluating the
safety and feasibility of conservative surgery in women with
early-stage cervical cancer [11]. Second, Gynecologic Oncol-
ogy Group protocol 278 (GOG-278) is evaluating the impact
of non-radical surgery on bladder, bowel, and sexual func-
tion and examining the incidence and severity of lymph-
edema after non-radical surgery [12]. The third is the
Gynecologic Cancer Intergroup trial by Plante and col-
leagues, known as the SHAPE trial. This is a randomized
controlled trial comparing the outcomes of radical hysterec-
tomy and simple hysterectomy in patients with low-risk cer-
vical cancer [13]. In addition, Japanese Clinical Oncology
Group protocol 1101 (JCOG-1101) is evaluating the non-
inferiority of modified radical hysterectomy as compared to
historical data of radical hysterectomy in overall survival for
patients with tumor diameter 2 cm or less [14]. However,
JCOG-1101 was not considered in this study as they permit-
ted some extent of parametrectomy.
Considering that patients are currently enrolled in trials
for less radical surgery, there is an urgent need to systemat-
ically evaluate the performance of the criteria used in on-
going studies in diverse clinical settings, where factors such
as surgical policies, imaging instruments, and pathologists’
experience differ. However, the actual risk of PMI in pa-
tients that satisfy the abovementioned criteria has not yet
been determined in diverse clinical settings. The aim of this
study was to evaluate whether the criteria used in three on-
going studies accurately identified low-risk patients for
PMI with acceptable false negativity, and to suggest a new,
simplified criterion using MRI findings in microscopic
Stage IB1 cervical cancer.
Methods
Patients
A retrospective chart review was performed using institu-
tional cervical cancer databases from 2003 to 2011, follow-
ing approval from the Institutional Review Board of Seoul
National University Hospital (Registration number: H-
1303-085-474) and in compliance with the Helsinki Dec-
laration. The data included patients’ clinical characteristics,
pathologic reports, and MRI findings. Patients were eligible
for inclusion if they (1) had no gross lesion on initial clin-
ical staging; (2) were microscopically diagnosed with Stage
IB1 cervical cancer after conization as pathologic reports
showed depth of invasion of more than 5 mm or width of
more than 7 mm; (3) had preoperative MRI after coniza-
tion (post-conization MRI); and (4) underwent type C2
radical hysterectomy and bilateral pelvic lymphadenectomy
within four weeks of diagnosis. Patients were excluded if
they received radiation or chemotherapy before surgery.
Consequently, 125 patients were eligible for analysis.
Clinical variables from the records include age, surgi-
cal procedures, type of adjuvant therapy, recurrence, and
progression-free survival (PFS). Pathologic variables
from conization specimens include histological type,
depth of invasion and width of tumor, margin status
(endocervical, exocervical, and deep margin), and lym-
phovascular space invasion (LVSI). Pathologic variables
from hysterectomy specimens include surgical margins
status, depth of invasion and width of residual tumor,
LVSI, lymph node status, and PMI.
Inclusion criteria from three ongoing studies
The inclusion criteria used in the three ongoing studies
are shown in Table 1. Medical records were reviewed to
identify possible candidates for less radical surgery based
on the inclusion criteria. Histologic subtypes, tumor
width and depth of invasion, and margin status from
conization specimens were evaluated. As all patients had
no visible tumors on clinical examination, all met the
criterion of tumor diameter less than 20 mm. Inclusion
criteria for ConCerv were no LVSI and negative margin
on conization. For GOG-278, lateral margin status and
depth of invasion (≤10 mm) on conization were evalu-
ated to identify candidates for less radical surgery. For
the SHAPE trial, patients with tumor size > 20 mm or
stromal invasion ≥ 50% on post-conization MRI were ex-
cluded from the less radical surgery group and coniza-
tion findings (depth of invasion < 10 mm) were used to
identify a low-risk group.
MRI and a new, simplified criterion
MRI was performed using a phased-array coil at 1.5 T
(Signa; GE Healthcare, Milwaukee, Wis) after conization.
We described the details of MRI protocols in a previous
report [2]. In addition, contrast-enhanced MRI was
obtained with axial fat-saturated T1-weighted gradient
recalled echo imaging before and at 1, 3, and 5 min after
intravenous bolus administration of contrast media
using 0.1 mmol/kg of gadopentetate dimeglumine
(Magnevist; Berlex Laboratories, Wayne, NJ, USA) or
gadoterate meglumine (Dotarem; Guerbet, Bloomington,
IN, USA) injected at a rate of 2 mL/s followed by a
20-mL saline flush using a power injector. In addition,
contrast-enhanced sagittal T1-weighted fast spin-echo
was acquired at 4 min after contrast administration.
MRI data were reviewed by a radiologist (J. Y. C.), who
was blind to surgical outcomes. The largest tumor diam-
eter was determined by measuring three dimensions on
thin-section axial and sagittal T2-weighted images of
cervical carcinoma.
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We suggested a new, simplified criterion for less rad-
ical surgery as patients with no demonstrable lesions on
post-conization MRI in microscopic Stage IB1 cervical
cancer. Using this criterion, patients were categorized
into two groups: MRI-invisible tumor and MRI-visible
tumor. MRI-invisible tumor was defined as cervical can-
cer that was not visible on either T2-weighted images or
contrast-enhanced T1-weighted images. MRI-visible
tumor was defined as cervical cancer that was slightly
hyperintense on T2-weighted images and where the
lesion was poorly enhanced on contrast-enhanced T1-
weighted images compared to the adjacent normal cer-
vical tissue [8].
Pathology specimen review
Conization and hysterectomy specimens were reviewed
separately. All gynecologic oncologists performed the
large loop excision of the transformation zone for coni-
zation. We described the details of this procedure in a
previous report [15]. Conization specimens were cut into
3 mm-thick radial blocks for pathologic evaluation. The
depth of stromal invasion was measured perpendicularly
from the basement membrane of the surface epithelium
by means of an ocular micrometer. Width of tumor was
measured in one direction along the surface epithelium
and perpendicular to the stromal infiltration. The mar-
gin status of conization specimens was evaluated separ-
ately for exocervical, endocervical, and deep margins. In
addition, surgical margin status, depth of invasion and
width of residual tumor, parametrial involvement, and
pelvic lymph node metastasis were evaluated from rad-
ical hysterectomy specimens. Parametrial involvement
was defined as the presence of tumor in either the para-
metrial nodes or tissue, including direct tumor growth
or spread via lymphovascular channels. Pathologic slides
were reviewed separately by an independent pathologist
(M. A. K.), who was blind to patient outcomes.
Statistical analysis
Standard statistical analysis was performed to calculate
descriptive statistics of the patient cohorts. Patients were
categorized into two groups (MRI-invisible and MRI-
visible tumors) based on post-conization MRI findings.
We used Student’s t-test and the Mann–Whitney U test
for continuous variables, according to normality, and the
chi-squared test or Fisher’s exact test for categorical var-
iables. PFS was defined as the time interval from surgery
to the first evidence of recurrence or death from any
cause, whichever occurred first. PFS curves were created
using the Kaplan–Meier method and the significance of
the survival curves was assessed with the log-rank test.
Rates of pathologic PMI were evaluated for patients that
satisfied the criteria used in ongoing studies and the
MRI criterion suggested in this study. All analyses were
performed using STATA 11.0 (StatCorp, College Station,
TX, USA). All P-values are two-sided.
Consent
Written informed consent was obtained from the patient
for the publication of this report and any accompanying
images.
Results
The characteristics of the 125 patients are presented in
Table 2. All patients in the study population had coniza-
tion followed by radical hysterectomy. The median age
was 47 years. Squamous cell carcinoma was most preva-
lent (76%), followed by adenocarcinoma (19.2%), and
adenosquamous carcinoma (4.8%). In conization speci-
mens, the median depth of invasion was 4 mm (range:
0.5-10 mm) and the median width was 12 mm (range:
2-42 mm). Overall, seven of the 125 patients (5.6%) had
PMI in the hysterectomy specimens.
Table 3 compares the clinicopathologic characteristics
of the two groups (MRI-invisible and MRI-visible). In
post-conization MRI, the mean diameter of residual
tumor was 5.5 mm (range: 0-36 m). The rate of PMI was
1.4% (1/74) for MRI-invisible tumors and 11.8% (6/51)
for MRI-visible tumors. Moreover, there were statisti-
cally significant differences in the pathologic findings
from hysterectomy specimens, including residual tumor,
lymph node metastasis, and PMI. Therefore, the rate of
adjuvant therapy after radical hysterectomy was signifi-
cantly higher for MRI-visible tumors than MRI-invisible
tumors (P = 0.009). Recurrent tumors were detected in
0% (0/74) of MRI-invisible tumors and 13.7% (7/51) of
MRI-visible tumors on follow-up. Five-year PFS was
Table 1 The criteria used in ongoing studies and a new, simplified criterion using MRI for less radical surgery
Study Stage Selection criteria Histology
ConCerv [11] IA2, or IB1 tumor size ≤ 2 cm, No LVSI, and negative margin on cone SCC, or AC*
GOG-278 [12] IA1(LVSI+), IA2, or IB1 tumor size ≤ 2 cm, negative lateral margins, and depth of invasion≤ 10 mm on cone SCC, AC, or ASC
SHAPE [13] IA2, or IB1 tumor size ≤ 2 cm and <50% stromal invasion on MRI, and depth of invasion < 10 mm
on cone (if performed)
SCC, AC, or ASC
MRI microscopic IB1 No demonstrable lesion on post-conization MRI SCC, AC, or ASC
*grade 1 or 2.
LVSI, lymphovascular space invasion; SCC, squamous cell carcinoma; AC, adenocarcinoma; ASC, adenosquamous cell carcinoma.
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100% in MRI-invisible tumors and 87.7% in MRI-visible
tumors (P = 0.018; Figure 1).
Of the 125 patients, candidates for less radical surgery
were identified based on the inclusion criteria suggested
in ongoing studies. The number of cases that met the in-
clusion criteria and the performance of the criteria from
each study are shown in Table 4. In the 11 patients that
satisfied the ConCerv criteria (negative margins and
LVSI on conization) and 14 patients that met the GOG-
278 inclusion criteria (negative lateral margins and depth
of invasion ≤ 10 mm on conization), the rate of PMI was
0%. Therefore, the negative predictive value for ConCerv
and GOG-278 criteria to identify less radical surgery
candidates was 100%. Of the 78 patients that satisfied
the SHAPE criteria (depth of invasion <10 mm on coni-
zation and tumor diameter ≤ 20 mm and stromal inva-
sion <50% in post-conization MRI), only one had PMI.
Of the 74 patients in the MRI-invisible group, only one
had PMI. The negative predictive value of the MRI cri-
terion (MRI-invisible tumor) to identify patients who
would not benefit from parametrectomy was 98.7%.
We use a Venn diagram to show the candidates for less
radical surgery and how they satisfying the various criteria
(Figure 2). In our cohort, ConCerv criteria were the most
conservative for identifying candidates for less radical sur-
gery, and patients designated as low risk using Concerv cri-
teria completely satisfied the GOG-278 criteria. In
addition, patients assigned as low-risk based on the GOG-
278 criteria completely satisfied the SHAPE and MRI cri-
teria. By using the SHAPE criteria we would have identified
more candidates for less radical surgery than by using the
ConCerv or GOG-278 criteria. Furthermore, 67 patients
satisfied the both SHAPE and MRI criteria. Of these 67 pa-
tients, only one patient had pathologic PMI. In this case,
the hysterectomy specimens showed residual tumor and
pelvic lymph node metastasis, despite no demonstrable le-
sions on post-conization MRI, and indicated only tumor
emboli within the lymph vascular channels in the parame-
trial tissue. Only seven patients identified as low risk based
on the MRI criterion (n = 74) did not meet the SHAPE cri-
teria, and 11 patients identified as low risk by the SHAPE
criteria (n = 78) did not satisfy the MRI criterion.
Discussion
In this study we retrospectively reviewed the applicabil-
ity of criteria used in ongoing studies at institutions in
Korea. Considering that few studies have validated the
characteristics of low-risk criteria used in ongoing stud-
ies, our study has value as it evaluated the performance
Table 2 Characteristics of study population (n = 125)
Variables N (%)
Age, median (range), year 47 (27–80)
Histology
Squamous cell 95 (76%)
Adenocarcinoma 24 (19.2%)
Adenosquamous carcinoma 6 (4.8%)
Conization findings
Depth of invasion, median (range), mm 4 (0.5-10)
Width of tumor, median (range), mm 12 (2–42)
Margin status
Positive exocervical RM 53 (42.4%)
Positive endocervical RM 93 (74.4%)
Positive deep RM 77 (61.6%)
Hysterectomy findings
Residual disease 70 (56%)
PMI 7 (5.6%)
Positive RM 1 (0.8%)
LN metastasis 17 (13.6%)
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Figure 1 Progression-free survival for microscopic Stage IB1
cervical cancer.









Age, median (range), year 45 (27–80) 48 (30–75) 0.337
Adjuvant treatment, n (%) 0.009
No 66 (89.2) 33(64.7)
RT 2 (2.7) 4 (7.8)
CCRT 6 (8.1) 14 (27.5)
Pathologic findings in hysterectomy
specimens, n (%)
Residual tumor 36 (48.6) 34 (66.7) 0.046
Parametrial involvement 1 (1.4) 6 (11.8) 0.013
Lymph node metastasis 6 (8.1) 11 (21.6) 0.031
Resection margin 0 (0) 1 (2.0) 0.433
RT, radiotherapy; CCRT, concurrent chemoradiotherapy.
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of the criteria used in three ongoing studies and com-
pared them simultaneously in one institution. In our in-
stitution, enrollment in ongoing studies would have
resulted in a failure to identify and treat a very small
subset of microscopic IB1 patients with PMI. In
addition, we demonstrated that patients with MRI-
invisible tumors in microscopic IB1 disease had minimal
risk of PMI and an excellent prognosis and, therefore,
were potential candidates for less radical surgery.
The study sample comprised 125 patients with micro-
scopically diagnosed IB1 cervical cancer who had clinically
invisible lesions. As tumor size is one of the most import-
ant factors for predicting PMI, patients without visible le-
sions may have a low risk of PMI. A low-risk group for
PMI in microscopic IB1 disease should be evaluated using
other parameters for macroscopic IB1 disease. In our pre-
vious study, we identified a low risk group for parametrial
involvement in macroscopic IB1 based on preoperative
MRI parameters [2]. In that study, all patients were with
clinical Stage IB1 cervical cancer and grossly visible lesions.
We should consider that conization is almost always per-
formed in microscopic IB1 disease, whereas conization is
rarely performed in macroscopic IB1 disease. Therefore,
post-conization MRI parameters or conization findings
such as margin status, depth of invasion, and LVSI were
evaluated to identify a low-risk group for PMI in a micro-
scopic IB1 disease subset.
Several studies have reported the oncologic outcomes
of patients with early-stage cervical cancer who under-
went less radical surgery, such as conization or simple
hysterectomy [16-19]. To date, 260 women with conser-
vatively managed early-stage cervical cancer have been
described in the literature and oncologic outcomes are
very favorable, with only two recurrences [10]. Consider-
ing these notable outcomes, patients are actively enrol-
ling in trials of less radical surgery around the world.
Although less radical surgery can be considered for pa-
tients with Stage IA2–IB1 disease in a clinical trial set-
ting, many clinicians still hesitate to perform less radical
surgery in practice or to enroll these patients in clinical
trials [9]. This may be for the following reasons. First,
concern about pathologic PMI was raised even in low-
risk groups; the actual risk of PMI in low-risk candidates
identified in ongoing studies has not been extensively
validated in diverse clinical settings. Second, the amount
of evidence supporting less radical surgery is currently
very weak; even for Stage IA2 cervical cancer patients,
evidence supporting less radical surgery is unclear due
to the lack of a randomized controlled trial [20].
We evaluated the performance of the criteria used in on-
going studies on less radical surgery. Each criterion defines
a subset of women presenting with cervical cancer that,
based on conization findings or preoperative MRI parame-
ters, could avoid morbidity–increasing parametrectomy at
the time of surgery based on the absence of PMI. In our
cohort, the ConCerv and GOG-278 criteria identified can-
didates for less radical surgery very conservatively, while
SHAPE and our new MRI criteria identified more candi-
dates with microscopic IB1 disease for less radical surgery
with a low likelihood of PMI and recurrence. Although fur-
ther studies with a larger sample are required to validate
these results, our study demonstrates that microscopic IB1
Table 4 Performance of the criteria used in ongoing studies and MRI criterion
Study No. of less radical
surgery candidate (%)
No. of PMI in less radical
surgery candidate (%)
Sensitivity Specificity NPV PPV
ConCerv 11 (8.8%) 0 (0%) 100% 9.3% 100% 6.1%
GOG-278 14 (11.2%) 0 (0%) 100% 11.9% 100% 6.3%
SHAPE 78 (62.4%) 1 (1.3%) 85.7% 65.3% 98.7% 12.8%
MRI 74 (59.2%) 1 (1.4%) 85.7% 61.9% 98.7% 11.8%
PMI, parametrial involvement; PPV, positive predictive value; NPV, negative predictive value.
Figure 2 Distribution of less radical surgery candidates
according to the various criteria. The area of square with gray per
white is proportional to the number of less radical surgery
candidates per study cohort. Study cohort, 100% (n = 125); ConCerv,
8.8% (n = 11); GOG-278, 11.2% (n = 14); SHAPE, 62.4% (n = 78); MRI,
59.2% (n = 74).
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cervical cancer patients classified as low risk may be ideal
candidates for less radical surgery and current ongoing
studies in this area may be considered safely.
As patients with clinically invisible tumors usually
undergo conization before radical hysterectomy in order to
clarify tumor width and depth of invasion, most patients
have the opportunity for a work-up such as MRI after coni-
zation. Therefore, we suggest a new criterion for less rad-
ical surgery in microscopic Stage IB1 cervical cancer based
on post-conization MRI findings. Considering that some
patients have endophytic tumor or residual tumor after
conization, post-conization MRI will give us useful infor-
mation to identify a low-risk group for PMI. Although
many practitioners consider preoperative MRI mandatory,
few studies have evaluated the diagnostic value of post-
conization MRI and its ability to help predict a low risk
group for PMI in early-stage cervical cancer [8,21].
Lakhman et al. showed that patients with no tumor at
post-conization MRI and with negative conization margins
were without tumors at pathologic specimens. Park et al.
reported 0% PMI with MRI-invisible IB1 cancers and bet-
ter survival outcomes than for MRI-visible IB1 cancer [8].
They showed that of 86 patients with MRI-invisible can-
cers, 51 underwent conization, and post-conization MRIs
more frequently indicated negative cancer findings in
patients with small tumors. In our study, all patients had
MRI after conization and 76 patients had MRI-invisible tu-
mors in post-conization MRI. The criteria suggested in this
study are practical and make it easy to identify low-risk
patients after conization in this disease subset. Our new
MRI criterion highlights the possibility of using simpler,
easier criteria that are not based on multiple variables, as
in the inclusion criteria for the SHAPE trial.
There are several limitations to this study. First, our
study has a retrospective design. The possibility of selection
bias could not be excluded completely. Second, although
the MRI-invisible tumor diagnosis was determined
from T2-weighted and post-contrast MRI, there is the pos-
sibility of inter-observer variation. In addition, new MRI
techniques, such as diffusion-weighted imaging, perfusion-
weighted imaging, and MRI spectroscopy, were not consid-
ered for measuring tumors in this study. Lastly, our new
MRI criterion was not validated in an independent set of
patients.
Conclusions
Despite these limitations, this is the first study to evaluate
the performance of criteria used in ongoing studies and in-
vestigate new criteria in microscopic IB1 cervical cancer.
In conclusion, the criteria used in ongoing studies identify
a low-risk group for PMI with a low likelihood of PMI.
This suggests that the vast majority of women could cor-
rectly avoid parametrectomy, with its potential increased
morbidity risk, if candidates for less radical surgery are
enrolled in these ongoing studies. In addition, new, simpli-
fied criteria using MRI findings can help identify patients
with a low risk of PMI in microscopic IB1 cervical cancer
and, therefore, potential candidates for less radical surgery.
Further studies with a large sample size are required to val-
idate the criteria used in ongoing studies and our new MRI
criterion.
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